"The
Report Gastric and Gastroesophageal Junction Adenocarcinoma - China
Drug Forecast and Market Analysis to 2024 provides information on
pricing, market analysis, shares, forecast, and company profiles for
key industry participants. - MarketResearchReports.biz"
Gastric
and gastroesophageal junction adenocarcinoma
(G/GEJAC) represents the majority of gastric cancer cases worldwide.
It is the fifth most diagnosed cancer globally, and the third most
common cause of cancer death in the world. The major treatments for
G/GEJAC are chemotherapy-based, but targeted therapies such as HER2
and angiogenesis inhibitors have been approved and are being added to
chemotherapy regimens since 2010 and 2014, respectively.
Although
China has the highest number of incident cases of G/GEJAC across the
8MM, the economic situation of the country has been limiting the
growth of the whole oncology pharmaceutical market due to the
combined effect of low treatment rate and low uptake of expensive
targeted therapies. GlobalData expects the growth of this market to
be driven by the increasing incidence of the disease in urban
populations, increased number of people covered by private health
insurance, increased access to branded biologics, and the uptake of
pipeline agents.
Download Sample copy of this
Report at : http://www.marketresearchreports.biz/sample/sample/754857
Scope
-
Overview of G/GEJAC including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines as well as an overview
on the competitive landscape.
-
Detailed information on the key drugs in China including product
description, safety and efficacy profiles as well as a SWOT analysis.
-
Sales forecast for the top drugs in China from 2014-2024.
-
Analysis of the impact of key events as well the drivers and
restraints affecting China G/GEJAC market.
Reasons to buy
-
Understand and capitalize by identifying products that are most
likely to ensure a robust return
-
Stay ahead of the competition by understanding the changing
competitive landscape for G/GEJAC.
-
Effectively plan your M&A and partnership strategies by
identifying drugs with the most promising sales potential
-
Make more informed business decisions from insightful and in-depth
analysis of drug performance
-
Obtain sales forecast for drugs from 2014-2024 in China.
Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and
Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Biomarkers/Targets of
Interest
3.2 Staging
3.3 Symptoms
3.4 Prognosis
3.5 Quality of Life
4 Disease Management
4.1 Diagnosis and Treatment
Overview
4.1.1 Screening
4.1.2 Diagnosis
4.1.3 Treatment Guidelines and
Leading Prescribed Drugs
4.1.4 Clinical Practice
4.2 China
4.2.1 Screening and Diagnosis
4.2.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 HER2-Targeted Therapy
5.2.1 Herceptin (trastuzumab)
5.3 Angiogenesis Inhibitors
5.3.1 Cyramza (ramucirumab)
5.3.2 Aitan (apatinib)
5.4 Chemotherapies
5.4.1 TS-1 (tegafur, gimeracil,
oteracil)
5.4.2 Abraxane (nab-paclitaxel)
6 Unmet Need and Opportunity
6.1 Overview
6.2 First-Line Therapy for
HER2-Negative Patients
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 New Molecular Targets for
Targeted Therapies
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Effective Perioperative and
Postoperative Therapies
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment